Treatment Information

Back

Melanoma treatment details. Immunotherapy.

Gustave Roussy Comprehensive Cancer Center, Paris, France.

Survival: monthsCountry:France
Toxiciy Grade:4City/State/Province:Paris
Treatments:ImmunotherapyHospital:Gustave Roussy Comprehensive Cancer Center
Drugs:Journal:Link
Date:Oct 2013

Description:

Patients:
This phase 3 study involved 657 melanoma patients with a median age of 54 years; 54.3% were male.

Treatment:
Patients were given immunotherapy with a vaccine called GM2-KLH/QS-21, which is a GM2 ganglioside vaccine that helps the immune system target tumor cells.

Toxicities:
The most severe toxicities were of grade 4 and included grade 3-4 fatigue, injection site reaction, and muscle pain.

Results:
The median overall survival was 15.48 months.

Support:
This study was supported by Progenics Pharmaceuticals.

Correspondence: Dr. Alexander M.M. Eggermont; email: [email protected]



Back